These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35838190)

  • 1. Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.
    Doi T; Shitara K; Kojima T; Kuboki Y; Matsubara N; Bando H; Yoh K; Naito Y; Hirai H; Kurokawa Y; Kato T; Morizane C
    Cancer Sci; 2023 Feb; 114(2):574-585. PubMed ID: 35838190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.
    Bahleda R; Meric-Bernstam F; Goyal L; Tran B; He Y; Yamamiya I; Benhadji KA; Matos I; Arkenau HT
    Ann Oncol; 2020 Oct; 31(10):1405-1412. PubMed ID: 32622884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring
    Meric-Bernstam F; Bahleda R; Hierro C; Sanson M; Bridgewater J; Arkenau HT; Tran B; Kelley RK; Park JO; Javle M; He Y; Benhadji KA; Goyal L
    Cancer Discov; 2022 Feb; 12(2):402-415. PubMed ID: 34551969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
    Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
    Javle M; King G; Spencer K; Borad MJ
    Oncologist; 2023 Nov; 28(11):928-943. PubMed ID: 37390492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
    Nogova L; Sequist LV; Perez Garcia JM; Andre F; Delord JP; Hidalgo M; Schellens JH; Cassier PA; Camidge DR; Schuler M; Vaishampayan U; Burris H; Tian GG; Campone M; Wainberg ZA; Lim WT; LoRusso P; Shapiro GI; Parker K; Chen X; Choudhury S; Ringeisen F; Graus-Porta D; Porter D; Isaacs R; Buettner R; Wolf J
    J Clin Oncol; 2017 Jan; 35(2):157-165. PubMed ID: 27870574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.
    Garmezy B; Borad MJ; Bahleda R; Perez CA; Chen LT; Kato S; Oh DY; Severson P; Tam BY; Quah CS; Harding JJ
    Cancer Res Commun; 2024 Apr; 4(4):1165-1173. PubMed ID: 38602417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Futibatinib for
    Goyal L; Meric-Bernstam F; Hollebecque A; Valle JW; Morizane C; Karasic TB; Abrams TA; Furuse J; Kelley RK; Cassier PA; Klümpen HJ; Chang HM; Chen LT; Tabernero J; Oh DY; Mahipal A; Moehler M; Mitchell EP; Komatsu Y; Masuda K; Ahn D; Epstein RS; Halim AB; Fu Y; Salimi T; Wacheck V; He Y; Liu M; Benhadji KA; Bridgewater JA;
    N Engl J Med; 2023 Jan; 388(3):228-239. PubMed ID: 36652354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients.
    Meric-Bernstam F; Hollebecque A; Furuse J; Oh DY; Bridgewater JA; Shimura M; Anderson B; Hangai N; Wacheck V; Goyal L
    Clin Cancer Res; 2024 Apr; 30(8):1466-1477. PubMed ID: 38329716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.
    Nishio M; Murakami H; Ohe Y; Hida T; Sakai H; Kasahara K; Imamura F; Baba T; Kubota K; Hosomi Y; Shimokawa T; Hayashi H; Miyadera K; Tamura T
    Invest New Drugs; 2019 Dec; 37(6):1207-1217. PubMed ID: 30790152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
    Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
    Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring
    Voss MH; Hierro C; Heist RS; Cleary JM; Meric-Bernstam F; Tabernero J; Janku F; Gandhi L; Iafrate AJ; Borger DR; Ishii N; Hu Y; Kirpicheva Y; Nicolas-Metral V; Pokorska-Bocci A; Vaslin Chessex A; Zanna C; Flaherty KT; Baselga J
    Clin Cancer Res; 2019 May; 25(9):2699-2707. PubMed ID: 30745300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours.
    Rodon J; Postel-Vinay S; Hollebecque A; Nuciforo P; Azaro A; Cattan V; Marfai L; Sudey I; Brendel K; Delmas A; Malasse S; Soria JC
    Eur J Cancer; 2017 Aug; 81():142-150. PubMed ID: 28624695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological characteristics and clinical effectiveness of Futibatinib (Lytgobi
    Takagaki K; Okude R; Hirayama N; Sootome H; Hirai H
    Nihon Yakurigaku Zasshi; 2024 Nov; 159(6):423-432. PubMed ID: 39384389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.
    Soria JC; DeBraud F; Bahleda R; Adamo B; Andre F; Dientsmann R; Delmonte A; Cereda R; Isaacson J; Litten J; Allen A; Dubois F; Saba C; Robert R; D'Incalci M; Zucchetti M; Camboni MG; Tabernero J
    Ann Oncol; 2014 Nov; 25(11):2244-2251. PubMed ID: 25193991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer.
    Saridogan T; Akcakanat A; Zhao M; Evans KW; Yuca E; Scott S; Kirby BP; Zheng X; Ha MJ; Chen H; Ng PKS; DiPeri TP; Mills GB; Rodon Ahnert J; Damodaran S; Meric-Bernstam F
    Sci Rep; 2023 Nov; 13(1):20223. PubMed ID: 37980453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors.
    Garralda E; Schram AM; Bedard PL; Schwartz GK; Yuen E; McNeely SC; Ribeiro S; Cunningham J; Wang Y; Urunuela A; Xu X; LoRusso P
    Oncologist; 2024 Jan; 29(1):e131-e140. PubMed ID: 37531083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors.
    Koyama T; Shimizu T; Iwasa S; Fujiwara Y; Kondo S; Kitano S; Yonemori K; Shimomura A; Iizumi S; Sasaki T; Furuse J; Yamamoto N
    Cancer Sci; 2020 Feb; 111(2):571-579. PubMed ID: 31797489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
    Tabernero J; Bahleda R; Dienstmann R; Infante JR; Mita A; Italiano A; Calvo E; Moreno V; Adamo B; Gazzah A; Zhong B; Platero SJ; Smit JW; Stuyckens K; Chatterjee-Kishore M; Rodon J; Peddareddigari V; Luo FR; Soria JC
    J Clin Oncol; 2015 Oct; 33(30):3401-8. PubMed ID: 26324363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.